Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 51
1993 62
1994 67
1995 77
1996 1
1997 12
1998 10
1999 92
2000 92
2001 100
2002 101
2003 168
2004 170
2005 227
2006 452
2007 369
2008 238
2009 319
2010 280
2011 263
2012 274
2013 260
2014 285
2015 316
2016 271
2017 299
2018 268
2019 297
2020 462
2021 337
2022 302
2023 393
2024 181

Text availability

Article attribute

Article type

Publication date

Search Results

6,755 results

Results by year

Filters applied: . Clear all
Page 1
Surgical site infection prevention bundle in gynecology oncology surgery: a key element in the implementation of an enhanced recovery after surgery (ERAS) program.
Ribero L, Santía MC, Borchardt K, Zabaneh F, Beck A, Sadhu A, Edwards K, Harrelson M, Pinales-Rodriguez A, Yates EM, Ramirez PT. Ribero L, et al. Int J Gynecol Cancer. 2024 Jun 14:ijgc-2024-005423. doi: 10.1136/ijgc-2024-005423. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38876786 Review.
Investigating age and ethnicity as novel high-risk phenotypes in mucinous ovarian cancer: retrospective study in a multi-ethnic population.
Olaoye T, - A, Boyle W, Williams A, Ganesan R, Subba K, Goyal A, Leung E, Chowdhary R, Pascoe J, Williams S, Yap J, Balega J, Kumar S, Singh K, Sundar SS. Olaoye T, et al. Int J Gynecol Cancer. 2024 Jun 11:ijgc-2024-005332. doi: 10.1136/ijgc-2024-005332. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38862154
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).
Salani R, McCormack M, Kim YM, Ghamande S, Hall SL, Lorusso D, Barraclough L, Gilbert L, Guzman Ramirez A, Lu CH, Sabatier R, Colombo N, Hu Y, Krishnan V, Molinero L, Feng Y, Kim N, Castro M, Lin YG, Monk BJ. Salani R, et al. Int J Gynecol Cancer. 2024 Jun 10:ijgc-2024-005588. doi: 10.1136/ijgc-2024-005588. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38858106
Notable surgical trials in gynecologic oncology: a 10-year overview.
Vilches JC, Santía MC, Yates EM, Pareja R, Lozano M, Ramirez PT. Vilches JC, et al. Int J Gynecol Cancer. 2024 Jun 10:ijgc-2024-005471. doi: 10.1136/ijgc-2024-005471. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38858104 Review.
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.
Coleman RL, Lorusso D, Oaknin A, Cecere SC, Denys H, Colombo N, van Gorp T, Konner JA, Romeo Marin M, Harter P, Murphy C, Wang Y, Esteves B, Method M, Matulonis U. Coleman RL, et al. Int J Gynecol Cancer. 2024 Jun 10:ijgc-2024-005401. doi: 10.1136/ijgc-2024-005401. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38858103
6,755 results